Use of GELSECTAN^® in Patients with Irritable Bowel Syndrome (IBS): an Italian Experience

References

• Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016;18:S0016-5085(16)00222–5. doi:10.1053/j.gastro.2016.02.031
   Web of Science ®Google Scholar
• Soncini M, Stasi C, Usai Satta P, et al.; AIGO. IBS clinical management in Italy: the AIGO survey. Dig Liver Dis. 2019;51(6):782–789. doi:10.1016/j.dld.2018.10.006
   Google Scholar
• Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99–114.e3. doi:10.1053/j.gastro.2020.04.014
   PubMed Web of Science ®Google Scholar
• Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med. 2012;367(17):1626–1635. doi:10.1056/NEJMra1207068
   PubMed Web of Science ®Google Scholar
• Mumolo MG, Rettura F, Melissari S, et al. Is gluten the only culprit for non-celiac gluten/wheat sensitivity? Nutrients. 2020;12(12):3785. doi:10.3390/nu12123785
   PubMed Web of Science ®Google Scholar
• Blake MR, Raker JM, Whelan K. Validity and reliability of the Bristol stool form scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2016;44(7):693–703. doi:10.1111/apt.13746
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920–924. doi:10.3109/00365529709011203
   PubMed Web of Science ®Google Scholar
• Portincasa P, Moschetta A, Baldassarre G, et al. Pan-enteric dysmotility, impaired quality of life and alexithymia in a large group of patients meeting ROME II criteria for irritable bowel syndrome. World J Gastroenterol. 2003;9(10):2293–2299. doi:10.3748/wjg.v9.i10.2293
   PubMed Web of Science ®Google Scholar
• Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122(5):1500–1511. doi:10.1053/gast.2002.32978
   PubMed Web of Science ®Google Scholar
• Bellini M, Gambaccini D, Stasi C, et al. Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol. 2014;20(27):8807–8820. doi:10.3748/wjg.v20.i27.8807
   PubMed Web of Science ®Google Scholar
• Bellini M, Rossi A. Is a low FODMAP diet dangerous? Tech Coloproctol. 2018;22(8):569–571. doi:10.1007/s10151-018-1835-9
   PubMed Web of Science ®Google Scholar
• Lucak S, Chang L, Halpert A, et al. Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. Therap Adv Gastroenterol. 2017;10(2):253–275. doi:10.1177/1756283X16663396
   PubMed Web of Science ®Google Scholar
• Ford AC, Sperber AD, Corsetti M, et al. Irritable bowel syndrome. Lancet. 2020;396(10263):1675–1688. doi:10.1016/S0140-6736(20)31548-8
   PubMed Web of Science ®Google Scholar
• Vicario M, González-Castro AM, Martínez C, et al. Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations. Gut. 2015;64(9):1379–1388. doi:10.1136/gutjnl-2013-306236
   PubMed Web of Science ®Google Scholar
• Piqué N, Gómez-Guillén MDC, Montero MP. Xyloglucan, a plant polymer with barrier protective properties over the mucous membranes: an overview. Int J Mol Sci. 2018;19(3):673. doi:10.3390/ijms19030673
   Web of Science ®Google Scholar
• Oshima T, Miwa H. Gastrointestinal mucosal barrier function and diseases. J Gastroenterol. 2016;51(8):768–778. doi:10.1007/s00535-016-1207-z
   PubMed Web of Science ®Google Scholar
• Allegrini A, Pavone D, Carluccio F. A randomized controlled trial comparing a xyloglucan-based nasal spray with saline in adults with symptoms of rhinosinusitis. Curr Med Res Opin. 2018;34(3):377–385. doi:10.1080/03007995.2017.1341402
   PubMed Web of Science ®Google Scholar
• Gnessi L, Bacarea V, Marusteri M, et al. Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial. BMC Gastroenterol. 2015;15(1):153. doi:10.1186/s12876-015-0386-z
   PubMed Web of Science ®Google Scholar
• Rolando M, Valente C. Establishing the tolerability and performance of tamarind seed polysaccharide (TSP) in treating dry eye syndrome: results of a clinical study. BMC Ophthalmol. 2007;7:5. doi:10.1186/1471-2415-7-5
   Google Scholar
• Eutamene H, Beaufrand C, Harkat C, et al. The role of mucoprotectants in the management of gastrointestinal disorders. Expert Rev Gastroenterol Hepatol. 2018;12(1):83–90. doi:10.1080/17474124.2018.1378573
   PubMed Web of Science ®Google Scholar
• Trifan A, Burta O, Tiuca N, et al. Efficacy and safety of gelsectan for diarrhoea-predominant irritable bowel syndrome: a randomised, crossover clinical trial. United European Gastroenterol J. 2019;7(8):1093–1101. doi:10.1177/2050640619862721
   PubMed Web of Science ®Google Scholar
• Urakawa H, Mimura M, Kajiwara K. Diversity and versatility of plant seed xyloglucan. Trends Glycosci Glycotechnol. 2002;14(80):355–376. doi:10.4052/tigg.14.355
   Web of Science ®Google Scholar
• Kulkarni AD, Joshi AA, Patil CL, et al. Xyloglucan: a functional biomacromolecule for drug delivery applications. Int J Biol Macromol. 2017;104(Pt A):799–812. doi:10.1016/j.ijbiomac.2017.06.088
   Web of Science ®Google Scholar
• Santos J, Musta V, Luca CM, et al. Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children. Expert Rev Gastroenterol Hepatol. 2021;15(3):325–331. doi:10.1080/17474124.2021.1833715
   PubMed Web of Science ®Google Scholar
• Serrano J, Puupponen-Pimiä R, Dauer A, et al. Tannins: current knowledge of food sources, intake, bioavailability and biological effects. Mol Nutr Food Res. 2009;53(Suppl S2):S310–S329. doi:10.1002/mnfr.200900039
   Web of Science ®Google Scholar
• Carlson JL, Erickson JM, Hess JM, et al. Prebiotic dietary fiber and gut health: comparing the in vitro fermentations of beta-glucan, inulin and xylooligosaccharide. Nutrients. 2017;9(12):1361. doi:10.3390/nu9121361
   PubMed Web of Science ®Google Scholar
• Eutamene H, Placide F, Tondereau V, et al. Tu1254 - protective effect of mucoprotectants and prebiotic combination on gut barrier impairment and visceral hypersensitivity induced by an acute stress in rat. Gastroenterology. 2018;154(6):S–916. doi:10.1016/S0016-5085(18)33080-4
   Web of Science ®Google Scholar
• Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395–402. doi:10.1046/j.1365-2036.1997.142318000.x
   PubMed Web of Science ®Google Scholar
• Gaskell SK, Snipe RMJ, Costa RJS. Test-retest reliability of a modified visual analog scale assessment tool for determining incidence and severity of gastrointestinal symptoms in response to exercise stress. Int J Sport Nutr Exerc Metab. 2019;29(4):411–419. doi:10.1123/ijsnem.2018-0215
   PubMed Web of Science ®Google Scholar
• Apolone G, Mosconi P. The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol. 1998;51(11):1025–1036. doi:10.1016/s0895-4356(98)00094-8
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483. doi:10.1097/00005650-199206000-00002
   PubMed Web of Science ®Google Scholar
• Hays RD, Sherbourne CD, Mazel RM. The RAND 36-item health survey 1.0. Health Econ. 1993;2(3):217–227. doi:10.1002/hec.4730020305
   PubMedGoogle Scholar
• Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305(6846):160–164. doi:10.1136/bmj.305.6846.160
   PubMed Web of Science ®Google Scholar
• Fani B, Bertani L, Paglianiti I, et al. Pros and cons of the SeHCAT test in bile acid diarrhea: a more appropriate use of an old nuclear medicine technique. Gastroenterol Res Pract. 2018;2018:2097359. doi:10.1155/2018/2097359
   Web of Science ®Google Scholar
• Del Valle-Pinero AY, Van Deventer HE, Fourie NH, et al. Gastrointestinal permeability in patients with irritable bowel syndrome assessed using a four probe permeability solution. Clin Chim Acta. 2013;418:97–101. doi:10.1016/j.cca.2012.12.032
   PubMed Web of Science ®Google Scholar
• Bonfrate L, Di Palo DM, Celano G, et al. Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients. Eur J Clin Invest. 2020;50(3):e13201. doi:10.1111/eci.13201
   PubMed Web of Science ®Google Scholar
• Andrae DA, Patrick DL, Drossman DA, et al. Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients. Health Qual Life Outcomes. 2013;11:208. doi:10.1186/1477-7525-11-208
   PubMed Web of Science ®Google Scholar
• Valentin N, Camilleri M, Altayar O, et al. Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis. Gut. 2016;65(12):1951–1959. doi:10.1136/gutjnl-2015-309889
   PubMed Web of Science ®Google Scholar
• Coëffier M, Gloro R, Boukhettala N, et al. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol. 2010;105(5):1181–1188. doi:10.1038/ajg.2009.700
   PubMed Web of Science ®Google Scholar
• Bertrand J, Ghouzali I, Guérin C, et al. Glutamine restores tight junction protein claudin-1 expression in colonic mucosa of patients with diarrhea-predominant irritable bowel syndrome. JPEN J Parenter Enteral Nutr. 2016;40(8):1170–1176. doi:10.1177/0148607115587330
   Web of Science ®Google Scholar
• Piche T. Tight junctions and IBS–the link between epithelial permeability, low-grade inflammation, and symptom generation? Neurogastroenterol Motil. 2014;26(3):296–302. doi:10.1111/nmo.12315
   PubMed Web of Science ®Google Scholar
• Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut. 2009;58(2):196–201. doi:10.1136/gut.2007.140806
   PubMed Web of Science ®Google Scholar
• Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut. 2006;55(10):1512–1520. doi:10.1136/gut.2005.085373
   PubMed Web of Science ®Google Scholar
• Ferrier L. Significance of increased human colonic permeability in response to corticotrophin-releasing hormone (CRH). Gut. 2008;57(1):7–9. doi:10.1136/gut.2007.129841
   Web of Science ®Google Scholar